Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2021, with a specific reporting date of October 14, 2021. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs).
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume (Shares) | Exchange |
|---|---|---|---|---|
| 2021-10-12 | Ordinary Shares (25p) | £14.2746 | 18,150.702 | London Stock Exchange (XLON) |
Note: The total volume represents the aggregate of 11 individual transactions listed in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine share acquisitions by executives and their associates resulting from the re-investment of dividends paid on October 7, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with regulatory requirements.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment plans, not open market purchases or sales.
- Participants: Transactions involved 11 individuals, including the CEO (Ms. E. Walmsley), President of Vaccines & Global Health (Mr. R. Connor), and other senior executives and their associates.
- Uniform Pricing: All shares were acquired at a uniform price of £14.2746 per share on October 12, 2021.
- Scope: This filing does not provide data on GSK's overall financial health, product pipeline, or market performance for the period.